← Back to headlines
PharmAla Biotech Secures $100 Million US Licensing Deal for MDMA Therapy
PharmAla Biotech has signed a term sheet for a significant $100 million U.S. licensing deal. The agreement pertains to its ALA-002 MDMA therapy, marking a major development for the company.
20 May, 15:12 — 20 May, 15:12
Sources
Showing 1 of 1 sources
Related Stories
German Farmers Face Significant Harvest Losses Due to Drought
18m ago
Home Depot Exceeds Q2 Earnings Estimates Amidst Stagnant Housing Market
31m ago
Mark Walter Reportedly Selling Off Sports Holdings After Lakers Deal
42m ago
US 30-Year Treasury Yields Reach Highest Level Since 2007 Amid Global Sell-Off
45m ago